Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
XKEM is not a scam, but a lot of investors got scammed on HTDS (yours truly), so I like keeping my HTDS buddies informed about the BEST PENNY STOCK in the market. The hot heads at HTDS keep calling it a Nigerian Scam, and I Have a lot of friends in XKEM and some came from the HTDS board. When I call XEKM a scam it is surly sarcastic.
Price going up on heavy volume, that says it all!
Nigerian scam up 16% today (XKEM), still better than HTDS scam.
GET READY FOR MARGE!
test
Small float, cool.
I know your in this DoubleK!!!!!
http://allafrica.com/stories/200703140746.html
Daily Trust (Abuja)
March 14, 2007
Posted to the web March 14, 2007
A United States based company, Xechem International Inc., is to build a seven-million-dollar plant in Abuja to produce sickle cell drug.
The plant will be engaged in commercial production of NICOSAN, a herbal medication for the management of sickle cell disease.
The drug, developed as NIPRISAN by scientists at the National Institute for Pharmaceutical Research and Development (NIPRD) at Idu, near Abuja, is a non-toxic natural herbal drug with extracts from plants derived in Nigeria.
"We have already secured a 1.2 million dollar- loan from the Nigeria Export and Import Bank (NEXIM) for investment in the construction of the plant," the chairman of Xechem International Inc., Dr. Ramesh Pandey, told the North America correspondent of the News Agency of Nigeria (NAN) in New York at the weekend.
"We are again talking with NEXIM Bank because they promised us another five million dollars, while the U.S.-EXIM Bank is also working on a facility for us to ensure the immediate take-off of the project."
He said the facility, to be located at SHESTCO Technology Park in Gwagwalada, Abuja, would be one of the most modern and state-of-the-art research and development drug plant in Africa.
Pandey said the plant would produce the sickle cell drug, formulated by NIPRD, and patent it to his company on commercial basis.
"We are working hard to bring NICOSAN to markets in Nigeria and subsequently to the US and other countries," he said.
On how he acquired the production rights, the company executive stated: "In 2002, I signed an agreement for the transfer of exclusive ownership and rights for the Research and Development, production and worldwide sales and marketing of NIPRISAN to Xechem International Inc.
"Thereafter, the Board of Directors of Xechem International Inc., agreed to register Xechem Pharmaceuticals (Nigeria) Limited in 2002 to develop NIPRISAN as NICOSAN for marketing in Nigeria and worldwide."
He said the plant, due to its closeness to raw materials, would run on full capacity and provide "plenty of opportunities for Nigerian farmers and so it will create employment for a great number of unemployed persons".
"As soon as the drug plant starts rolling out, it will earn Nigeria foreign exchange," he said.
"Meanwhile, we are already producing this drug on a smaller scale as we are supplying the ones we are reproducing now to sickle cell patients."
Relevant Links
West Africa
Nigeria
Health and Medicine
United States, Canada and Africa
On the potency of the drug, he said NICOSAN is not a curative drug.
Pandey also disclosed that "as long as the patient takes his or her dose daily, there will not be crisis." "As a matter of fact, consistent use of NICOSAN reduces significant incident of crisis".
NAN learnt that the drug has been granted Orphan Drug status by the U.S. Food and Drug Administration and the EU's European Medical Evaluation Agency, which gives Xechem between seven to 10 years of exclusive production and marketing privileges.
Do your research, there is revs.
More Nigerian SCAM news: LOL love making money with real companies.
Xechem Updates the Progress on NICOSAN(TM) Manufacturing Capacity in Nigeria
Mar 13, 2007 06:30:01 (ET)
NEW BRUNSWICK, N.J., Mar 13, 2007 (BUSINESS WIRE) -- Xechem International, Inc. (XKEM, Trade ) announced today that its subsidiary Xechem Pharmaceuticals Nigeria Ltd. expects at least a significant increase in its pilot scale production of NICOSAN(TM) with the arrival of a long awaited and very important piece of equipment in Nigeria. The device, a second spray dryer, will be joined by a third spray dryer currently in transit and scheduled to arrive in a few weeks. Installation of the second spray dryer just received is already underway; it should be operational within the next ten days.
Dr. Ramesh C. Pandey, the Chairman and CEO, stated, "With this acquisition, we can increase our pilot scale production dramatically, allowing us to bring NICOSAN(TM) to as many as 30,000 patients per month within the next 90 days, which would result in sales of approximately US$500,000 per month, assuming we are successful in scaling up and marketing and distributing the product. We have sufficient raw materials on hand to handle this increase in production and are poised to begin operations of the full scale commercial manufacturing facility when construction is presently scheduled to be completed during the 4th quarter of this year. Upon our ability to raise sufficient funds to complete construction of our full scale facility on a timely basis, the Company believes it could produce sufficient product to serve the needs of approximately 50,000 to 100,000 patients by year end. Our current price of the product could in such event generate approximately $1 million to $2 million per month. Construction of our new manufacturing plant is continuing while we attempt to close on current funding proposals.
Funding and construction update:
1. Xechem Nigeria Construction: The production facility construction in Nigeria has been slowed by the lack of sufficient funding. The contractors remain supportive and have continued to work despite delays in their scheduled payments based, in part, on their confidence in Xechem Nigeria's ability to close the various pending loan transactions. Xechem Nigeria will be updating the company website ( www.xechemnigeria.com ) in the coming week. Please refer to the "gallery" section under the Xechem Nigeria website ( http://xechemnigeria.com/gallery.htm ) to view updated pictures of the construction progress. As Xechem Nigeria proceeds toward completion of the facility, stockholders will be kept informed.
2. Loan Status: US Ex-Im Bank: Xechem Pharmaceuticals Nigeria Ltd. ("XPNL") has now secured Final Commitment letters from two local Nigerian banks, Diamond Bank and Bank PHB, required by US Ex-Im Bank ("EXIM") when it approved a comprehensive credit guarantee to support UPS Capital's $9.38 million loan to XPNL in October 2006.
Initially, Access Bank was expected to be one of the two local guaranteeing banks, but it has now been replaced by Bank PHB. Though that switch slowed the process to allow Bank PHB to go through the Ex-Im Bank approval process, all required paperwork has now been completed for the "change over" from Access to Bank PHB and we are hopeful that EXIM will conclude all the formalities to close the loan in the upcoming weeks. The closing of the EXIM loan would help cover the cost of acquiring the plant equipment and machinery needed from various US venders to equip the commercial scale production facility in Nigeria.
3. Loan Status: Nigerian Ex-Im Bank: Xechem Nigeria has been in long-standing negotiations with Nigerian Export-Import Bank ("NEXIM") to secure an additional loan of approximately $5 million (Five Million US Dollars) to fund the completion of the commercial scale production facility and to provide interim working capital. Previously, NEXIM had loaned to Xechem Nigeria N150 Million Naira ($1.2 million US Dollars), which was used to facilitate the expansion of its facility for the commercial scale production of NICOSAN(TM), its promising Sickle Cell drug. In late February 2006, the Management Committee of NEXIM approved the additional sum of N350 Million Naira (approx. $2.6 million US Dollars) as the second phase funding, with the hope to fund an additional funding of N285 (approx. $2.2 million US Dollars) in third phase loans.
4. NICOSAN(TM) Market Update in Nigeria: The reports from the patients using NICOSAN(TM) in Nigeria have been very positive and demand is continuing to increase on a world-wide basis. Xechem is tracking patients using NICOSAN(TM) in order to assure those patients already on the drug maintain a continued supply as the Company grows. Xechem Nigeria recently passed an unannounced inspection of its facilities by the Nigerian drug regulators NAFDAC.
About NICOSAN(TM)
NICOSAN(TM) is an anti-sickling drug originally developed as NIPRISAN by the Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD's auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN(TM) no longer experience sickle cell "crises" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced. Through quality control/quality assurance (QC/QA) Xechem has standardized and verified the antisickling activity of the product, which is now called as NICOSAN(TM).
After the approval by the regulatory agency of Nigeria, National Agency for Food and Drug Administration and Control (NAFDAC), NICOSAN(TM) is being marketed in Nigeria since July 6th, 2007 on a limited basis. NICOSAN(TM) has Orphan Drug Designation in the US and EU countries.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (natural herbal drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).
Pfizer, ,it went up with Viagra. ;)
This stock is in the clouds man.
http://www.stockcloud.net/stock/HTDS/
NBNB
fgsdgdsa
Shareholders News Update on Artec, Inc.
Feb 5 2007, 2:53 PM EST
Business Wire
On February 1, 2007, at 3:00 p.m., Artec, Inc. (Pink Sheets: ATKJ) and Shinn Capital Group, Inc., learned that Dr. Tai-Ho Chung and Chong Chan Chung had assigned their Tubercin patents to Hyolim Bio Co., Ltd., of Korea. It was recorded on 11/30/2006. A shareholder brought this matter to our attention.
The attorney representing both Shinn Capital Group, Inc., and Artec, Inc., Mr. Phillip Offill, is contacting the appropriate party responsible for the retraction of this assignment which is considered not legal and not in the best interest of Artec, Inc., and Shinn Capital Group, Inc. No matter what happens, we have been assured that Artec, Inc., and Shinn Capital Group, Inc., are still the lawful owners of Tubercin that are supported by court decisions. We will post the results as soon as we know the outcome of our inquiry.
In the meantime, Artec, Inc., is determined and prepared upon funding, to proceed to produce Tubercin. Our position is Dr. Chung is a principal partner of Artec, Inc. He owns 8% ownership of Artec, Inc. stocks and cannot jeopardize the company by leaving or assigning his patent to someone else, in terms of SEC compliance. We will keep you posted on this situation as well.
In addition, there was favorable court ruling on December 12, 2006, by the United Stated Court of Appeals 11th Circuit Number 05-14737. The Court of Appeals reaffirmed the US Federal District Court Judgment that basically affirms Shinn Capital Group Inc., as the lawful owner of Tubercin and that Hard To Treat Diseases, Inc. of Florida has no legal rights.
We are pleased with this legal outcome and will proceed toward project closure in the near future. We will announce the news of a project closure as soon as possible. Management wants to thank everyone for their continued support, especially the Artec, Inc. shareholders.
The company cautions the investors that forward-looking statements in this press release involve risks and uncertainties pursuant to the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, the company cautions investors that it undertakes no obligations or responsibilities to publicly update these forward-looking statements to reflect Company's expectation with regard to these forward-looking statements or the occurrence of unanticipated events.
http://www.genengnews.com/news/bnitem.aspx?name=12321633
Xechem did not pay the amounts due Alembic on December 31, 2006. Xechem and Alembic have been in negotiations regarding an extension of the Maturity Date. Pursuant to a Letter Agreement, dated January 4, 2007, the parties agreed to extend the Maturity Date to January 31, 2007. The parties may extend the Maturity Date further, pending additional negotiations of an extension agreement and the successful completion of due diligence
Is there any building going on?
What story?
At least you admit it.
PLEASE!!!!!!!!!!!!!!!!!!!
efeeff
qegwerger
test
Here we go!
This week.
gOOD LUCK
vvvv
test
twst
test
CYBL has been popular for the last year, played with it alittle bit, these are good levels to get in,
I'll keep you updated on next news (XKEM). Not to pump, just if you want to make money. ;)
Exactly
This forum is strictly entertainment.
My boss's broker sold his Cavit shares for 3 cents each, a whopping $1300.
MM's love the action of this stock, but long term you will be rewarded.
Will only dump half at .50 :
Read the bottom of YAHOO'S FINANCE PAGE:
http://finance.yahoo.com/
OT: XKEM
Hey doubleloser, scam just gets better:
http://www.alphatrade.com/news/stories/AM/2007-01-03/BIZ/200701031003BIZWIRE_USPR_____BW5722.html
Thanks JoChef
Thanks bigd.